Marc Carrier, M generic viagra .D., Alejandro Lazo-Langner, M.D., Sudeep Shivakumar, M.D., Vicky Tagalakis, M.D., Ryan Zarychanski, M.D., Susan Solymoss, M.D., Nathalie Routhier, M.D., James Douketis, M.D., Kim Danovitch, C.C.R.P., Agnes Y. Lee, M.D., Gregoire Le Gal, M.D., Philip S. Wells, M.D., Daniel J. Corsi, Ph.D., Timothy Ramsay, Ph.D., Doug Coyle, Ph.D., Isabelle Chagnon, M.D., Zahra Kassam, M.D., Hardy Tao, M.D., and Marc A. Rodger, M.D. For the SOME Investigators: Screening for Occult Cancers in Unprovoked Venous Thromboembolism.
Research Patients We recruited individuals for the active-control research from 265 sites in 33 countries and for the placebo-control study from 147 sites in 21 countries. Sufferers were eligible if they had been at least 18 years and had objectively confirmed, symptomatic, proximal deep-vein thrombosis or pulmonary embolism that had recently been treated with an approved anticoagulant or if they experienced received dabigatran in one of two previous clinical trials of short-term treatment of venous thromboembolism: the RE-COVER3 and RE-COVER II4 studies. The main difference between your two trials in the selection of patients was that participants in the active-control study were regarded as at increased risk for recurrent venous thromboembolism based on the site investigator’s assessment.